The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Idiopathic multicentric Castleman disease (iMCD) comprises approximately 30% of all cases of Castleman disease. It is characterized by constitutional symptoms, enlarged lymph nodes at multiple anatomical sites, and laboratory test abnormalities, which are primarily related to the overproduction of interleukin 6 (IL-6). Siltuximab is a human-mouse chimeric immunoglobulin G1κ monoclonal antibody against human IL-6. In view of the limited treatment options for iMCD, this study aimed to evaluate the efficacy and safety of siltuximab in the management of this condition. Methods: In this real-world retrospective study, we administered siltuximab to 15 patients with iMCD who previously received conventional chemotherapy and/or steroid pulse therapy. The median time to a durable symptomatic response was 22 days (range, 17 to 56). The serum hemoglobin and albumin levels and erythrocyte sedimentation rates significantly normalized after the first 3 months of siltuximab treatment. Lymph node involution, assessed using imaging, was relatively gradual, demonstrating a complete or partial response at 6 months. Results: On an average, the improvements in clinical, laboratory, and radiologic parameters of iMCD in responders were observed after one, three, and eight cycles of siltuximab treatment, respectively. Siltuximab demonstrated a favorable safety profile, and prolonged treatment was well-tolerated. Conclusions: Despite the small sample size of the present study, the results are encouraging and demonstrate the potential of siltuximab as the first-line treatment of iMCD. Further large multicenter studies are needed to evaluate the clinical outcomes and adverse events associated with siltuximab.
Abstract
Background/Aims: Idiopathic multicentric Castleman disease (iMCD) comprises approximately 30% of all cases of Castleman disease. It is characterized by constitutional symptoms, enlarged lymph nodes at multiple anatomical sites, and laboratory test abnormalities, which are primarily related to the overproduction of interleukin 6 (IL-6). Siltuximab is a human-mouse chimeric immunoglobulin G1κ monoclonal antibody against human IL-6. In view of the limited treatment options for iMCD, this study aimed to evaluate the efficacy and safety of siltuximab in the management of this condition. Methods: In this real-world retrospective study, we administered siltuximab to 15 patients with iMCD who previously received conventional chemotherapy and/or steroid pulse therapy. The median time to a durable symptomatic response was 22 days (range, 17 to 56). The serum hemoglobin and albumin levels and erythrocyte sedimentation rates significantly normalized after the first 3 months of siltuximab treatment. Lymph node involution, assessed using imaging, was relatively gradual, demonstrating a complete or partial response at 6 months. Results: On an average, the improvements in clinical, laboratory, and radiologic parameters of iMCD in responders were observed after one, three, and eight cycles of siltuximab treatment, respectively. Siltuximab demonstrated a favorable safety profile, and prolonged treatment was well-tolerated. Conclusions: Despite the small sample size of the present study, the results are encouraging and demonstrate the potential of siltuximab as the first-line treatment of iMCD. Further large multicenter studies are needed to evaluate the clinical outcomes and adverse events associated with siltuximab.
참고문헌 (16)
- Castleman B, "Localized mediastinal lymphnode hyperplasia resembling thymoma", Cancer, 9, pp.822~830 (1956)
- Castleman B, "Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot", N Engl J Med, 251, pp.396~400 (1954)
- Talat N, "Surgery in Castleman’s disease: a systematic review of 404 published cases", Ann Surg, 255, pp.677~684 (2012)
- Dispenzieri A, "The clinical spectrum of Castleman’s disease", Am J Hematol, 87, pp.997~1002 (2012)
- Gaba AR, "Multicentric giant lymph node hyperplasia", Am J Clin Pathol, 69, pp.86~90 (1978)
- Keller AR, "Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations", Cancer, 29, pp.670~683 (1972)
- Simpson D, "Epidemiology of Castleman disease", Hematol Oncol Clin North Am, 32, pp.1~10 (2018)
- Casper C, "The aetiology and management of Castleman disease at 50 years : translating pathophysiology to patient care", Br J Haematol, 129, pp.3~17 (2005)
- van Rhee F, "Castleman disease in the 21st century : an update on diagnosis, assessment, and therapy", Clin Adv Hematol Oncol, 8, pp.486~498 (2010)
- Nishimoto N, "Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease", Blood, 106, pp.2627~2632 (2005)
- Fajgenbaum DC, "HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy", Blood, 123, pp.2924~2933 (2014)
- van Rhee F, "Siltuximab for multicentric Castleman’s disease : a randomised, double-blind, placebo-controlled trial", Lancet Oncol, 15, pp.966~974 (2014)
- van Rhee F, "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease", J Clin Oncol, 28, pp.3701~3708 (2010)
- van Rhee F, "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease", Blood, 132, pp.2115~2124 (2018)
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Fajgenbaum DC, "Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease", Blood, 132, pp.2323~2330 (2018)